Programme
Meeting 2017

European Network to Cure ALS
18 - 20 May, Ljubljana, Slovenia

Programme

Organised by:
European Network to Cure ALS

Local Organisers:
Ljubljana ALS Centre, Institute of Clinical Neurophysiology
University Medical Centre Ljubljana, Slovenia
Slovenian Society of Clinical Neurophysiology
Contents

Welcome Address .......................................................... 3

Committees ..................................................................... 4

Scientific Programme ..................................................... 7

Poster Sessions .............................................................. 14

Registration and Fees ..................................................... 32

General Information ....................................................... 33
Dear colleagues,

Amyotrophic lateral sclerosis (ALS) is a devastating disease that is still lacking an effective cure. In recent years, research advances offer hope that ALS will eventually become a preventable and treatable disease. Patients, researchers and clinicians worldwide have joined forces in various international projects to make progress towards this goal. European Network to Cure ALS (ENCALS) is a network of ALS centres in Europe that supports such collaborations. 2017 is an exciting year for the ALS community since positive clinical drug trials are promising new treatments after more than two decades.

The Ljubljana ALS Centre at the Institute of Clinical Neurophysiology, University Medical Centre Ljubljana was established in 2002 to offer multidisciplinary clinical care for the Slovenian patients with ALS. In the past 15 years, we have cared for more than 500 patients. Our research encompasses neurophysiology, neuroimaging, genetics and epidemiology of ALS. We are collaborating with other Slovenian and international research centres.

It is my pleasure to welcome you to the ENCALS Meeting 2017, taking place at the Cankarjev dom Cultural and Congress Centre in Ljubljana, Slovenia. The meeting is hosted by the Ljubljana ALS Centre and the Slovenian Society of Clinical Neurophysiology. In three days, a series of plenary lectures, thematic sessions and poster presentations will bring together international researchers and clinicians to discuss the advances in research and clinical care. As always the meeting is also an excellent opportunity to meet colleagues and friends and to start new collaborations.

Besides the main programme, there are numerous satellite meetings and events, including the 8th Annual Scientific Meeting of the Thierry Latran Foundation and the 3rd TRICALS Workshop Outcome Measures. I would also like to welcome the participants of the ALS Health Practitioners Forum, the first inaugural meeting of nurses, speech therapists, physiotherapists and occupational therapists providing ALS care.

I would like to thank Prof. Orla Hardiman, Prof. Leonard van den Berg and all the members of the Programme and Organising Committees for their input and support, Mrs. Akke Albada from the ENCALS Office and Mrs. Alenka Kregar from the Cankarjev dom Congress and Events Management for turning many complications into a smoothly organised event, and all the sponsors for their generous contribution.

I can promise you that an interesting meeting programme will effectively keep you away from exploring our beautiful city. Which means that you will leave with a good reason to visit us again soon.

Dobrodošli v Ljubljani!

Blaž Koritnik
On behalf of the Local Organising Committee
Committees

Programme Committee
Orla Hardiman, Chair (Ireland)
Caterina Bendotti (Italy)
Jochen Weishaupt (Germany)
Janine Kirby (England)
Blaž Koritnik (Slovenia)
Janez Zidar (Slovenia)
Boris Rogelj (Slovenia)

Local Organising Committee
Blaž Koritnik, Chair
Janez Zidar
Boris Rogelj
Lea Leonardis
Leja Dolenc Grošelj
Stanka Ristič Kovačič
Polona Klinar
Dušan Dumić
Tanja Trdič
Boštjan Kastelic

ENCALS Executive Board
Chair:
Leonard van den Berg (The Netherlands)
Vice Chair:
Orla Hardiman (Ireland)
Treasurer:
Adriano Chio (Italy)
Albert Ludolph (Germany)
Wim Robberecht (Belgium)
Kevin Talbot (England)
Markus Weber (Switzerland)
Pamela Shaw (England)

Jesus Mora Pardina (Spain)
Peter Andersen (Sweden)
Francois Salachas (France)
Magdalena Kuzma (Poland)
Sharon Abrahams (Scotland)
Julian Grosskreutz (Germany)
Ammar Al Chalabi,
Chair Award Committee
(England)
Award Committee
Ammar Al-Chalabi, Chair (England)
Markus Weber (Switzerland)
Mamede de Carvalho (Portugal)
Sharon Abrahams (Scotland)
Pamela Shaw (England)
Susanne Petri (Germany)
Ludo van den Bosch (Belgium)
Luc Dupuis (France)

ENCALS Office
Mrs. Akke Albada
Phone: +31 88 755 1221
E-mail: info@encals.eu
Web: www.encals.eu

Conference Secretariat
CANKARJEV DOM, Cultural and Congress Centre
Mrs. Alenka Kregar
Prešernova 10, SI-1000 Ljubljana, Slovenia
Phone: +386 1 24 17 133
Fax: +386 1 24 17 296
E-mail: alenka.kregar@cd-cc.si
Web: www.cd-cc.si/en/

Venue
Cankarjev dom, Cultural and Congress Centre
Prešernova 10, SI-1000 Ljubljana, Slovenia
Phone: +386 1 24 17 100
Acknowledgements

The Organising Committee would like to thank the following sponsors for their generous support:

**Golden Sponsor**

Cytokinetics

**Bronze Sponsors**

Orion Pharma

patientslikeme®
Thursday, 18 May

12:00-13:30  Registration and lunch / Second Foyer

LINHART HALL

Chairs: Leonard van den Berg, Janez Zidar

13:30-13:45  Opening session

13:45-14:15  Dr. Janez Faganel memorial lecture: Prof. Jernej Ule (London, UK)
“Protein-RNA complexes & ALS: insights from iCLIP”

14:15-15:00  Thierry Latran Foundation lecture:
Dr. Jesús S. Mora (Madrid, Spain), Prof. Luis Barbeito (Montevideo, Uruguay), Prof. Olivier Hermine (Paris, France)
“Masitinib as an add-on therapy to riluzole is beneficial in the treatment of amyotrophic lateral sclerosis (ALS) with acceptable tolerability: Results from a randomized controlled phase 3 trial”

15:00-16:00  Session I: Therapy

Joseph M. Palumbo: Efficacy and safety of edaravone (MCI-186) for the treatment of amyotrophic lateral sclerosis (ALS): A 24-week extension

Ammar Al-Chalabi: ODM-109 (oral levosimendan): Key placebo-controlled results from the phase 2 study in ALS patients with SVC between 60-90% predicted at screening

Joseph M. Scarrott: Bringing gene therapy based SOD1 silencing towards human trials: A highly efficacious, off-target free and biomarker supported strategy for fALS

Franziska Bursch: Intraspinal injection of human mesenchymal stromal cells in SOD1G93A ALS mice

16:00-16:30  Coffee break
Chairs: Magdalena Kuzma, Markus Weber

16:30–17:30  **Session 2: Clinical & Epidemiology**

**James P. K. Rooney:** Euro-MOTOR: A multi-centre population-based case-control study of metals and solvents exposure as risk factors for amyotrophic lateral sclerosis

**Alexander Sherman:** Global ALS/MND “big data” collaboration environment in a post-PRO-ACT era

**Nayana Gaur:** The time of the ALSFRS-R to decrease to 50% (D50) in a sigmoidal decay model sufficiently describes the complete disease course of ALS

**Fabrizio D’Ovidio:** The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis

17:30–19:00  **Poster session 1 / Second Foyer**

---

**Friday, 19 May**

**LINHART HALL**

07:30–08:00  Coffee reception for AB Science satellite meeting

08:00–09:00  **AB Science satellite meeting:**

**Luis Barbeito** (Montevideo, Uruguay), **Jesús S. Mora** (Madrid, Spain), **Olivier Hermine** (Paris, France):

Masitinib for the treatment of amyotrophic lateral sclerosis (ALS):

Preclinical overview and future clinical development
Chairs: Adriano Chiò, Julian Grosskreutz

09:00-09:45 Invited lecture: Dr. Federica Agosta (Milano, Italy) “Tracking ALS progression using neuroimaging”

09:45-10:45 Session 3: Genetics A

Chen Eitan: Discovery of microRNA gene mutations in ALS patient genomes

Matthieu Moisse: Whole genome sequencing as tool to unravel rare variants associated with ALS survival

Alex Freischmidt: Serum microRNA-profiles indicate a role of Fragile-X-related proteins for ALS

Rick van der Spek: The Project MinE data browser: bringing whole-genome sequencing data in ALS to researchers and the public

10:45-11:15 Coffee break

Chairs: Peter Andersen, Jochen Weishaupt

11:15-12:00 Invited lecture: Dr. Russell McLaughlin (Dublin, Ireland) “The panorama of ALS genomics”

12:00-13:00 Session 4: Genetics B

Ahmad Al Khleifat: Integrating copy-number analysis with structural-variation detection in 50 ALS patients with two extreme survival phenotypes

Gijs H. P. Tazelaar: ATXN1: Expanding the spectrum of polyglutamine repeats in ALS

Alfredo Iacoangeli: A high throughput gene, environment and epigenetics database and analysis system for international ALS research

Monica Nizzardo: microRNAs analysis of patient-derived iPSCs as molecular therapy for ALS

13:00-13:15 Late breaking news

Albert Ludolph: A placebo-controlled investigator initiated trial (IIT) to evaluate the efficacy, safety and tolerability of 1 mg rasagiline in patients with amyotrophic lateral sclerosis (ALS) receiving standard therapy (riluzole)

13:15-14:15 Lunch / Second Foyer
**LINHART HALL**

**Chairs: Sharon Abrahams, Blaž Koritnik**

14:15-15:00  **Invited lecture: Dr. Thomas Bak** (Edinburgh, UK)  
"Cognitive and behavioural symptoms in ALS: why are they there and how to assess them?"

15:00-16:00  **Session 5: Cognition & Imaging**

**Ratko Radakovic**: The Brief Dimensional Apathy Scale (b-DAS): Mokken analysis and scale reduction

**Marta Pinto-Grau**: Assessing behaviour in ALS: the importance of using disease-specific tools

**Martin Gorges**: Hypothalamic atrophy correlates with onset of disease-defining symptoms in patients with ALS

**Giovanni Novi**: A PET/CT approach to spinal cord metabolism

16:00-16:30  **Coffee break**

**Chairs: Albert Ludolph, Luc Dupuis**

16:30-17:30  **Session 6: Disease mechanisms A**

**Gina Picchiarelli**: Role of FUS in post synaptic neuromuscular junction differentiation

**Doris Lou Demy**: Developing vertebrate models to highlight the functional relevance of Nefl and miRNAs in ALS pathogenesis

**Steven Boeynaems**: Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics

**Tariq Afroz**: Dynamic polymerization of TDP-43 in health and disease

17:30-19:00  **Poster session 2 / Second Foyer**

20:30  **ENCALS dinner / Festival Hall**
LINHART HALL

Chairs: Ammar Al-Chalabi, Ludo van den Bosch

09:00-09:15  Poster award for PhD students

09:15-09:30  ENCALS Young Investigator Award

09:30-10:15  Invited lecture: Janine Kirby (Sheffield, UK)
              „Gene Expression Profiling in ALS: Past, Present and Future“

10:15-11:15  Session 7: Disease mechanisms B

Hortense de Calbiac: Deciphering the function and mechanisms of C9ORF72 in ALS

Raphael Munoz-Ruiz: Live imaging of RNA dynamics for genetic forms of amyotrophic lateral sclerosis (ALS) in zebrafish

Jasna Brčić: Two G-quadruplex structures adopted by oligonucleotide model of ALS and FTD linked GGGGCC repeats

Veronica Ferrari: The role of valosin containing protein (VCP) in the clearance of toxic misfolded protein aggregates in amyotrophic lateral sclerosis

11:15-11:45  Coffee break

Chairs: Caterina Bendotti, Boris Rogelj

11:45-12:45  Session 8: Disease mechanisms C

Ana Bajc Česnik: Intranuclear (G4C2)n RNA foci, transcribed from C9ORF72 hexanucleotide expansion mutation, form paraspeckle-like structures

Yolanda Gibson: C9orf72 interacts with coilin and influences Cajal body dynamics and splicing

Bart Swinnen: Direct RNA toxicity in a transient zebrafish model of C9orf72 ALS is abrogated by PURA and p62

Stephanie Duguez: Secretion of toxic exosomes by muscle cells of ALS patients: role in ALS pathogenesis

12:45-13:00  Closing of the meeting
Satellite meetings and side meetings

**Wednesday, 17 May**

**Room E 6**
09:00-12:00  Thierry Latran Foundation Scientific Advisory Board meeting

**E 1 Hall**
13:30-18:30  Satellite meeting: 8th Annual Scientific Meeting of the Thierry Latran Foundation – by invitation only

**Second Foyer**
18:30-20:00  Thierry Latran Foundation standing buffet – by invitation only

**Thursday, 18 May**

**E 1 Hall**
09:00-12:00  Satellite meeting: 8th Annual Scientific Meeting of the Thierry Latran Foundation

**Room E 6**
09:00-12:00  OnWebDuals Project meeting

**M1 Hall**
19:00-20:00  Project MinE meeting

**Lili Novy Club**
20:00-22:00  Cytokinetics Investigator Reception (closed meeting)
Friday, 19 May

Linhart Hall
08:00-09:00  AB Science satellite meeting

M2 Hall
13:15-14:15  ENCALS Executive Board meeting

E1,2 Hall
09:30-18:00  Satellite meeting:
             ALS Health Care Practitioners Forum

M1 Hall
17:30-18:30  Strength/ALS-CarE Project meeting

Saturday, 20 May

E1 Hall, M1 Hall, M3,4 Hall, E 2 Hall
09:30-13:00  Satellite meeting:
             TRICALS Workshop Outcome Measures (session for research nurses)
13:00-14:00  TRICALS lunch (for TRICALS centres)
14:00-19:00  Satellite meeting:
             TRICALS Workshop Outcome Measures (for TRICALS centres)
20:00-23:00  TRICALS dinner (for TRICALS centres)

Sunday, 21 May

E1 Hall, M1 Hall, M3,4 Hall, E 2 Hall
09:00-13:00  Satellite meeting:
             TRICALS Workshop Outcome Measures (for TRICALS centres)
             Information for Speakers and Poster Presenters
Poster Session I

Thursday, 17:30-19:00

Biomarkers

P1
TDP-43-based biomarker development in ALS
Emily Feneberg, Elizabeth Gray, David Gordon, Kevin Talbot, Martin R. Turner

P3
Phosphorylated neurofilament heavy chains in blood as biomarker for ALS?
Maxim De Schaepdryver, Benjamin Gille, Victor Herbst, Britta Brix, Philip Van Damme, Andreas Jeromin, Koen Poesen

P5
Proteomic analysis in postmorten neurological tissue of subjects with amyotrophic lateral sclerosis (ALS)
Marina Iridoy, Leyre Martínez, Victoria Zelaya, Enrique Santamaría, Joaquin Fernández-Irigoyen, Ivonne Jericó

P7
Internal control genes validation for qPCR analysis in lymphocytes from patients with amyotrophic lateral sclerosis
Ewa Usarek, Beata Kaźmierczak, Beata Gajewska, Anna Barańczyk-Kuźma, Magdalena Kuźma-Kozakiewicz

P9
Blood polyunsaturated fatty acid composition is a biomarker for amyotrophic lateral sclerosis
Laura Robelin, Alexandre Henriques, François Salachas, Hélène Blasco, Gabrielle Rudolf, Martine Bergaentzle, Marie-Céline Fleury, Christian Andres, Philippe Corcia, Eric Marchioni, Jean-Philippe Loeffler, Pierre-François Pradat, Jose-Luis Gonzalez De Aguilar

PI1
The synergistic effect of IL-2, IL-6, IL-10, IL-13 and eotaxin influence longevity in transgenic SOD1G93A mice
Laura Moreno-Martínez, Ana C. Calvo, Miriam de la Torre, Janne M. Toivonen, Leticia Moreno-García, Nora Molina, Gabriela Atencia-Cibreiro, Pilar Zaragoza, Alberto García-Redondo, Rosario Osta
Expression of macrophage scavenger receptor (MSR 1) in patients with motor neuron disease
Beata Chełstowska, Beata Gajewska, Beata Kaźmierczak, Anna Barańczyk-Kuźma, Magdalena Kuźma-Kozakiewicz

Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity in ALS and other neurodegenerative diseases
Juan F Vázquez-Costa, José I. Tembl, Victoria Fornés-Ferrer, Fernando Cardona, Lluis Morales-Caba, Gerardo Fortea, Jordi Pérez-Tur, Teresa Sevilla

The TGFß- system – a critical factor in disease progression of amyotrophic lateral sclerosis (ALS)

Clinical

Use of noninvasive ventilation in the treatment of ALS in Europe versus in the US: results of an international ALS specialist survey
Leonard van den Berg, Merit Cudkowicz, Mamede de Carvalho, Angela Genge, Orla Hardiman, Carlayne Jackson, Noah Lechtzin, Hiroshi Mitsumoto, Vincenzo Silani, Jinsy Andrews, Sarah Kulke, Stacy Rudnicki, Terry Heiman-Patterson

Living wills for amyotrophic lateral sclerosis’s disease patients: a psychological and integral health care perspective
Noemi Morales, Anna Camps, Laura Baget, Sandra Blavi

Secular trends of ALS incidence in an Italian population-based register, 1995-2014: evidence for a birth cohort effect in women
Adriano Chiò, Gabriele Mora, Cristina Moglia Umberto Manera, Antonio Canosa, Stefania Cammarosano, Antonio Ilardi, Davide Bertuzzo Enrica Bersano, Paolo Cugnasco, Maurizio Grassano, Fabrizio Pisano, Letizia Mazzini, Andrea Calvo
P25
Dry mass slope is a predictive factor in amyotrophic lateral sclerosis
Franck Patin, Areej Alrabiah, Salah Eddine Bakkouche, Stéphane Bletran, Christian R. Andrès, Patrick Vourc’h, Hélène Blasco, Philippe Corcia

P27
The natural history of dysphagia in ALS: a population-based study
Cristina Moglia, Andrea Calvo, Antonio Canosa, Stefania Cammarosano, Antonio Ilardi, Fabrizio Pisano, Gabriele Mora, Enrica Bersano, Letizia Mazzini, Umberto Manera, Adriano Chiò

P29
Spatio-temporal assessment of the association between environmental exposures and the occurrence of amyotrophic lateral sclerosis (ALS)
Maria Barceló, Marc Saez, Andrés Paipa, José Luis Moreno, Mònica Povedano

P31
Advance directives and the decision-making process in an ALS Unit in Spain
Amparo Martínez, Juan F. Vázquez-Costa

P33
Exploring respiration and swallowing interaction by diaphragm motor evoked potentials in ALS patients
Nazan Şimşek Erdem, Ferda İlgen Uslu, Selen Bozkurt, Hilmi Uysal

P35
A diagnostic pathway in Polish patients with ALS
Krzysztof Nieporecki, Katarzyna Szacka, Magdalena Kuzma-Kozakiewicz

P37
Assessment of the functional state of ALS patients in relation to physical activity
Jan Sznajder, Magdalena Kuźma-Kozakiewicz

P39
ONWebDUALS: the European project funded by national agencies under the patronage of Joint Programme – Neurodegenerative Disease Research (JPND)
M. de Carvalho, P. M. Andersen, M. Gromicho, J. Grosskreutz, M. Kuźma-Kozakiewicz, S. Petri, M. Piotrkiewicz, T. Podsiadły-Marczykowska, B. Stubendorf, K. Szacka, H. Uysal

P41
Motor neuron disease: a clinical case with unexpected evolution
Costanza Bisordi, Elena Caldarazzo Ienco, Monica Fabbrini, Michela Rossi, Anna Rocchi, Lucia Chicco, Gabriele Siciliano
Cognition

P43
Age- and education-adjusted cut-off scores for the German parallel versions of the ECAS

P45
Slovenian version of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS)
Ana Štublar, Petra Prunk, Vita Štukovnik, David Gosar, Janez Zidar, Leja Dolenc Grošelj, Lea Leonardis, Blaž Koritnik

P47
Premorbid neuropsychiatric disease in patients with motor neuron disease in Scotland
Danielle Leighton, Louise Manson, Caroline McHutchison, Laura Sherlock, Judith Newton, Laura Stephenson, Shuna Colville, Sharon Abrahams, Siddharthan Chandran, Suvankar Pal

P49
The contribution of social cognition to social behaviour: cognitive predictors of behavioural change in ALS
Tom Burke, Marta Pinto-Grau, Katie Lonergan, Orla Hardiman, Niall Pender

Genetics

P51
ATXN1 intermediate-length polyQ expansions are associated with C9orf72 ALS
Serena Lattante, Maria Grazia Pomponi, Amelia Conte, Giuseppe Marangi, Giulia Bisogni, Agata Katia Patanella, Emiliana Meleo, Marcella Zollino, Mario Sabatelli

P53
Novel UBQLN2 mutations linked to amyotrophic lateral sclerosis and spastic paraplegia through defective proteolysis
Elisa Teyssou, Laura Chartier, Roselina Lam, Maria-Del-Mar Amador, Géraldine Lautrette, Marie Nicol, Selma Machat, Sandra Da Barroca, Carine Moigneu, Mathilde Mairey, Thierry Larmontier, Safaa Saker, Christelle Dussert, Sylvie Forlani, Bertrand Fontaine, Danielle Seilhean, Delphine Bohl, Séverine Boillée, Philippe Couratier, François Salachas, Giovanni Stevanin, Stéphanie Millecamps
TBCE mutations cause early-onset progressive encephalopathy with distal spinal muscular atrophy

New FLG4 gene mutation causing fast progressing ALS phenotype: a case report
Giorgia Querin, Virginia Bozzoni, Cinzia Bertolin, Ilaria Martinelli, Cinzia Gellera, Elena Pegoraro, Gianni Sorarù

A retrospective analysis of the genotype–phenotype relationships in familial MND and MND–FTD within a South London population
James Bashford, Caroline Hitchen, Bradley Smith, Christopher Shaw

Intermediate CAG repeats in the ATXN2 gene in patients with amyotrophic lateral sclerosis from a Brazilian Research Center
Jessica Ruivo Maximino, Joyce Meire Gilio, Frederico Mennucci de Haidar Jorge, Gerson Chadi

SOD1, TDP-43, FUS/TLS and C9orf72 genes in Serbian ALS patients: long term survey
Dušan Keckarević, Milena Janković, Milica Gagić, Milica Keckarević Marković, Miljana Kecmanović, Ana Marjanović, Ivan V. Marjanović, Ivana Novaković, Zorica Stević

Neuroimaging patterns along the ALS–FTD spectrum: a multiparametric imaging study
Eoin Finegan, Taha Omer, Siobhan Hutchinson, Mark Doherty, Alice Vajda, Russell McLaughlin, Niall Pender, Orla Hardiman, Peter Bede

A 18FDG-PET study on ApoE genotype in ALS
Andrea Calvo, Antonio Canosa, Angelina Cistaro, Cristina, Cristina Moglia, Maura Brunetti, Barbara Iazzolino, Marco Pagani, Adriano Chiò
Myelin imaging in amyotrophic lateral sclerosis: a comparison with multiple sclerosis using quantitative magnetisation transfer
Marwa Elamin, Elizabeth Emsley, Rebecca Broad, Nick Dowell, Matt Gabel, Jamie Campbell, Waqar Rashid, Nigel P. Leigh, Mara Cercignani

The role of iron-related hypointensities on brain MRI as a biomarker in amyotrophic lateral sclerosis
Juan F. Vázquez-Costa, Miguel Mazón, Joan Carreras, David Hervás, Jordi Pérez-Tur, Luis Martí-Bonmatí, Teresa Sevilla

Mechanisms of disease

Synaptotagmin 13 protects motor neurons from degeneration in ALS
Monica Nizzardo, Federica Rizzo, Michela Taiana, Silvia Tamanini, Ilary Allodi, Julio Aguila Benitez, Jik Nijssen, Gianna Ulzi, Valentina Melzi, Roberto Del Bo, Nereo Bresolin, Giacomo Pietro Comi, Eva Hedlund, Stefania Corti

Establishing a patient-derived organoid model for studying cortical thinning in ALS
Renata Vieira de Sá, Paul R. Ormel, Lynn van der Beek, Sandra Kling, Lot D. de Witte, Elly M. Hol, Leonard H. van den Berg, Jeroen R. Pasterkamp

Stress granules formation upon condition of chronic stress in human ALS fibroblasts
Claudia Colombrita, Valentina Gumina, Annamaria Maraschi, Alberto Doretti, Cinzia Tiloca, Vincenzo Silani, Antonio Ratti

Molecular characterization of mouse optineurin insufficiency models
Andrea Markovinović, Tereza Ljutić, Ivana Munitić

Implication of peripheral macrophages in amyotrophic lateral sclerosis
Aude Chiot, Sakina Zaïdi, Charlène Iltis, Laure Bernard, Bertrand Calippe, Delphine Bohl, Stéphanie Millecamps, Christian S. Lobsiger, Séverine Boillée

Mutant superoxide dismutase aggregates from human ALS spinal cord transmit templated aggregation and fatal ALS disease in mice
Elaheh Ekhtiari Bidhendi, Johan Bergh, Per Zetterström, Karin Forsberg, Bente Pakkenberg, Peter M. Andersen, Stefan L. Marklund, Thomas Brännström
P85
Axonal transcriptome of stem cell-derived motor neurons in health and ALS
Jik Nijssen, Julio Cesar Aguila, Rein Hoogstraaten, Shangli Cheng, Qiaolin Deng, Eva Hedlund

P87
Evaluating the interdependence of misfolded SOD1 species in ALS pathogenesis
Desseille Céline, Peyrard Sarah, Vande Velde Christine

P89
Translating ribosome affinity purification from C9orf72-ALS/FTD patient-derived iPS Motor Neurons
Chaitra Sathyaprakash, Jakub Scaber, Nidaa Ababneh, Ruxandra Dafinca, Kevin Talbot

P91
The capacity to maintain stress granule assembly is impaired by a preceding chronic stress – the “first hit” can sensitise neurons to the “second hit”
Tatyana Shelkovnikova, Haiyan An, Mikhail Kukharsky, Natalia Ninkina, Vladimir Buchman

P93
The homeoprotein Engrailed 1 in spinal motor neuron survival
Stephanie Vargas, Stéphane Nedelec, Alain Prochiantz, Kenneth L. Moya

P95
Glial cell morphology, intracellular SOD1 distribution and elemental composition in the brainstem and hippocampus of the transgenic rat model of ALS
Stefan Stamenković, Tanja Dučić, Vera Stamenković, Alexander Kranz, Pavle R. Andjus

P97
Development of a virally-induced TDP-43 in vivo model of ALS
Barbara Scherz, Vera Niederkofler, Nicole Taub, Robert Zimmermann, Birgit Hutter-Paier

P99
Investigating the modifying role of EphA4 forward signaling in amyotrophic lateral sclerosis
Laura Rué, Lies Schoonaert, Mieke Timmers, Ludo Van Den Bosch, Philip Van Damme, Robin Lemmens, Wim Robberecht
P101
Phenotypic screening of PrP-hFUS-WT3 mouse model
Eveliina Pollari, Elisabeth Rossaert, Tom Jaspers, Roman Vangoitsenhoven, Bart Van der Schueren, Carla Cirillo, Pieter Vanden Berghe, Philip Van Damme, Wim Robberecht, Ludo Van Den Bosch

P103
Dual role of MHCI pathway in the development and progression of ALS in mouse models
Giovanni Nardo, Maria Chiara Trolese, Mattia Verderio, Julio Aguila Benitez, Jik Nijssen, Laura Comley, Eugenio Erba, Nicolò Panini, Nilo Riva, Giorgia Dina, Angelo Quattrini, Staffan Cullheim, Eva Hedlund, Caterina Bendotti

P105
Molecular characterization of a TDP-43 loss of function endothelial phenotype
Katrin Strecker, Bettina Pitter, Miha Modic, Vincenzo Caprese, Sebastian Lewandowski, Alexander Hruscha, Stefan Bonn, Eloi Montanez, Bettina Schmid

P107
TDP43 fragments clearance in a muscle model of sporadic ALS
M. E. Cicardi, V. Crippa, P. Rusmini, R. Cristofani, V. Ferrari, G. Vezzoli, M. Meroni, M. Galbiati, B. Tedesco, A. Poletti

P109
Inwardly rectifying potassium channel Kir4.1 in microglial cell clusters in the hSODG93A rat model
Mina Perić, Danijela Bataveljić, Pavle R. Andjus

P111
Expression of ALS-linked TDP-43 c-terminal domain reduces β-adrenergic-mediated cAMP signalling in cultured astrocytes
Jelena Velebit, Sonja Prpar Mihevc, Boris Rogelj, Robert Zorec, Nina Vardjan

P113
Excitability and calcium homeostasis of mutant SOD1-D90A iPSC derived motor neurons
Norman Kalmbach, Reto Eggenschwiler, Max Naujock, Zhangyou Zhu, Tobias Cantz, Florian Wegner, Susanne Petri

P115
Gene profiling of human iPSC-derived motor neurons from sporadic ALS patients reveals a participation of mitochondria in the autonomous mechanisms
Gerson Chadi, Jessica Ruivo Maximino, Frederico Mennucci de Haidar Jorge, Chrystian Junqueira Alves
Therapy

P117
A novel human in vitro model of motor neuron disease (MND) uncovers individual patient response to antioxidant drugs
Sufana Al Mashhadi, Monika Myszczynska, Matthew Stopford, Richard Mead, Pamela J. Shaw, Laura Ferraiuolo

P119
NF-κB constitutively activated in astrocytes enhances microglia response and induces a biphasic effect on MNs performance during ALS disease course
Najwa Ouali Alami, Christine Schurr, Tobias Boeckers, Thomas Wirth, Albert Ludolph, Bernd Baumann, Francesco Roselli

P121
Biomarkers of inflammation in long-term G-CSF treated ALS patients

P123
Dysregulation of ROCK and ERK in SOD1G93A mice: combinatorial ROCK/ERK-inhibition as possible therapeutic approach?
Nadine Thau-Habermann, Sarah Pederson, Niko Hensel, Julia Kauder, Peter Claus, Susanne Petri

P125
An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among individuals with ALS
Koji Takei, Manabu Hirai, Fumihiro Takahashi, Kikumi Tsuda, and Joseph M. Palumbo

P127
Human mesenchymal stem cell therapy reduces neuroinflammation in earlier symptomatic stages of ALS in SOD1-G93A mice
Gabriela B. Chiarotto, Mateus Vidigal de Castro, Adriana S. S. Duarte, Angela C. M. Luzo, Alexandre L. R. Oliveira
Biomarkers

P2
Vascular basement membrane proteins in plasma of ALS patients are associated with degree of cortical perfusion and age at sporadic disease onset
Sebastian A. Lewandowski, Julia Remnståhl, Anna Häggmark, Mun-Gwan Hong, Peter Lönneberg, Koen Poesen, Koen Van Laere, Ulf Eriksson, Philip Van Damme, Peter Nilsson

P4
Analysis of chitotriosidase activity in plasma and CSF as a candidate biomarker for amyotrophic lateral sclerosis
Leyre Martínez-Merino, Marina Iridoy, Blanca Acha, Miren Roldán, Adriana Rivero, Pilar Irún, Miguel Pocoví, Maite Mendioroz, Ivonne Jericó

P6
Lipidomic signatures in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

P8
TDP-43 function in nervous tissue is essential for physiological autophagy
Pascual Torres, Omar Ramírez-Núñez, Gisel Barés, Ana B. Granado-Serrano, Victòria Ayala, Jordi Boada, Laia Fontdevila, Monica Povedano, Daniel Sanchís, Reinald Pamplona, Isidro Ferrer, Manuel Portero-Otín

P10
Autoimmunity profiling of amyotrophic lateral sclerosis plasma
Jennie Olofsson, Julia Remnståhl, Sebastian Lewandowski, Jan Veldink, Anna Månberg, Peter Nilsson

P12
Small fiber neuropathy characterization in the SOD1G93A ALS mouse model
M. A. Rubio, M. Herrando-Grabulosa, J. J. Vilches, X. Navarro

P14
Protein array enabled profiling of autoantibody repertoires in ALS, ALS-FTD and FTD
Julia Remnståhl, Jennie Olofsson, Anna Häggmark-Månberg, Sebastian Lewandowski, Peter Nilsson
Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients
Jean-Baptiste Delaye, Franck Patin, Eric Piver, Clément Bruno, Marina Wasse, Patrick Vourc’h, Christian R. Andres, Philippe Corcia, Hélène Blasco

Expression of carnitine/acylcarnitine translocase in patients with motor neuron disease
Beata Gajewska, Beata Chelstowska, Beata Kaźmierczak, Anna Barańczyk-Kuźma, Magdalena Kuźma-Kozakiewicz

Multidisciplinary care improves survival of patients with ALS – evidence from the Ljubljana ALS Centre
Polona Klavžar, Blaž Koritnik, Lea Leonardis, Leja Dolenc Grošelj, Mojca Kirbiš, Stanka Ristić Kovačič, Polona Klinar, Dušan Dumić, Janez Zidar

The phenotypical variability of ALS and its relationship with survival. A 25 year experience in Catalonia
Montserrat Alemany, Carlota Mendez del Barrio, Andres Paipa, Raul Domínguez, Abdel Assialiuoi, Mónica Povedano

Infrastructure and resources for ALS research
Maya Bronfeld, Idit Ron, Shay Rishoni

Relevance of the methodology for analysing results – the SNIP model in amyotrophic lateral sclerosis
Susana Pinto, Mamede de Carvalho

Survival in amyotrophic lateral sclerosis and its dependency on slow and forced vital capacity
Susana Pinto, Mamede de Carvalho
P30
Existential decision-making in ALS. A comparison of legal and medical frameworks in Germany, Poland and Sweden
Christian Weber, Anna Lindblad, Gisela Badura-Lotter, Barbara Fijalkowska, Katarzyna Ciecwiwerska, Peter Andersen, Magdalena Kužma-Kozakiewicz, Albert Ludolph, Tomasz Pasierski, Niels Lynöe, Dorothée Lulé

P32
Motor nerve biopsy in motor neuron disease and motor neuropathy: clinical, prognostic and therapeutic implications
Nilo Riva, Francesco Gentile, Federica Cerri, Yuri Falzone, Francesca Gallia, Paola Podini, Giorgia Dina, Sandro Iannaccone, Christian Lunetta, Massimo Corbo, Raffaella Fazio, Eduardo Nobile-Orazio, Giancarlo Comi, Angelo Quattrini

P34
In ALS patients hypoventilation and cough inefficacy correlate with functional performance decline on the 6MWT

P36
End-of-life decisions in ALS: from physicians’ perspective
Krzysztof Barc, Helena Aho-Özhan, Dorothee Lule, Magdalena Kuzma-Kozakiewicz

P38
Does wellbeing of patients with amyotrophic lateral sclerosis depend on their population of origin?
Katarzyna Ciecwiwerska, Anna Maksymowicz-Śliwińska, Krzysztof Nieporęcki, Beata Pilczuk, Natalia Szejko, Jan Sznajder, Dorothée Lulé, Peter M. Andersen, Albert C. Ludolph, Magdalena Kužma-Kozakiewicz

P40
Amyotrophic lateral sclerosis domain ontology (DALSO) – first results
T. Podsiadły-Marczykowska, M. Kužma-Kozakiewicz, Maria Piotrkiewicz

Cognition

P42
A conceptual multi-modal cognitive model of affective social cognition (MASC) in amyotrophic lateral sclerosis
Tom Burke, Marta Pinto-Grau, Katie Lonergan, Emmet Costello, Orla Hardiman, Niall Pender
Digit Span Forward, a brief and simple test useful for predicting prognosis in ALS
Lucia Catherine Greco, Andrea Lizio, Gabriella Rossi, Matteo Querzola, Valeria Ada Sansone, Christian Lunetta

A secondary analysis of the Reading the Mind in the Eyes Test within ALS: the development of a rapid and reliable short form
Tom Burke, Marta Pinto-Grau, Katie Lonergan, Emmet Costello, Orla Hardiman, Niall Pender.

Is there an association between attention-deficit/hyperactivity disorder (ADHD) and amyotrophic lateral sclerosis (ALS)?
Leonie Ebel, Susanne Petri, Martina de Zwaan

Preliminary evaluation of hopelessness and depression in patients with amyotrophic lateral sclerosis undergoing a Mesenchymal Stem Cell clinical trial
Maiara Gonçalves Gedo, Mirian Akiko Furutani de Oliveira, Jessica Ruivo Maximino, Gerson Chadi

Investigation of new generation sequencing technologies and variant calling methods on Whole Genome Sequencing and Miseq data of ALS patients

CHCHD10 variants in amyotrophic lateral sclerosis: where is the evidence?
Gijs Tazelaar, Wouter van Rheenen, Project MinE ALS Sequencing Consortium

Unexpanded C9ORF72 alleles are not ALS risk factors

ALS in Turkey: recent insights from genetic studies
Ceren Tunca, Fulya Akçimen, Cemile Koçoğlu, Hamid Hamzeiy, Cemre Coşkun, Betül Uysal, Güneş Birdal, Aslı Gündoğdu Eken, Åslihan Özoğuz, A. Nazlı Başak
SMN2 gene copy number and promoter methylation as disease modifiers of childhood-onset spinal muscular atrophy
Miloš Brkušanin, Ana Kosać, Vladimir Jovanović, Jovan Pešović, Goran Brajušković, Vedrana Milić Rašić, Dušanka Savić-Pavičević

First report of angiogenin gene mutations in patients with amyotrophic lateral sclerosis in Serbia
Milena Janković, Ivan Marjanović, Ana Marjanović, Stojan Perić, Ivana Basta, Ivana Novaković, Zorica Stević

Genetic heterogeneity of amyotrophic lateral sclerosis in the Hungarian population
Kornélia Tripolszki, Dóra Nagy, Bernadett Csányi, Antonia Ratti, Cinzia Tiloca, Vincenzo Silani, József I. Engelhardt, Péter Klivényi, Nikoletta Nagy, Mártá Szell

Age and education – protective factors against cognitive decline in ALS indicated by intrinsic functional connectivity patterns
Markus Loose, Michael Wagner, Jürgen Keller, Helena E. A. Aho-Özhan, Sarah Böhm, Ingo Uttner, Hans-Peter Müller, Martin Gorges, Jan Kassubek, Albert C. Ludolph, Dorothée Lulé

Imaging profiles of ALS-FTD cohorts: looking beyond C9orf72
Eoin Finegan, Taha Omer, Siobhan Hutchinson, Mark Doherty, Alice Vajda, Russell McLaughlin, Niall Pender, Orla Hardiman, Peter Bede

Relationship between brain metabolism and cognitive/behavioral functioning in ALS
Joke De Vocht, Stefanie M. A. Willekens, Jordy Evens, Dorothy Gors, Donatienne Van Weehaeghe, Peter Claes, Koen Van Laere, Philip Van Damme

Spinal cord multi-parametric MRI for survival prediction in ALS
Giorgia Querin, Mounir El Mendili Mohamed, Timothée Lenglet, Véronique Marchand-Pauvert, Habib Benali, Pierre-François Pradat
Mechanisms of disease

P74
Modelization of intrinsic motor neuron defects in amyotrophic lateral sclerosis with human Induced Pluripotent Stem cells
Cynthia Lefebvre, Carine Dalle, Boris Lamotte d’Incamps, Stéphane Blanchard, Guillaume Tournaire, Diana Toli, Charles Nicaise, François Salachas, Lucette Lacomblez, Christian Lobsiger, Stéphanie Millecamps, Séverine Boillée, Delphine Bohl

P76
Motor neurons derived from induced pluripotent stem cells of patients with mutations in TARDBP show axonal transport defects
Raheem Fazal, Laura Fumagalli, Wenting Guo, Wim Robberecht, Catherine Verfaillie, Ludo Van Den Bosch, Philip Van Damme

P78
ALS patient-derived astrocytes: a high throughput model for drug screening
Matthew Stopford, Monika Myszczynska, Richard Mead, Laura Ferraiuolo

P80
Novel combinatorial screening identifies neurotrophic factors for selective classes of ALS-relevant motor neurons
Sébastien Schaller, Dorothée Buttigieg, Alysson Alory, Arnaud Jacquier, Marc Barad, Mark Merchant, David Gentien, Pierre de la Grange, Georg Haase

P82
Macrophage migration inhibitory factor as a potential therapeutic candidate for familial ALS
Adrian Israelson

P84
Muscle microRNAs: small RNA sequencing and differential expression in Slovenian patients and healthy age-matched controls
Anja Kovanda, Lea Leonardis, Janez Zidar, Blaž Koritnik, Leja Dolenc Grošelj, Stanka Ristič Kovačič, Tomaž Curk, Boris Rogelj

P86
TBI causes a transient elevation of pTDP-43-positive cytoplasmic granules in ALS-relevant mouse models
Diana Wiesner, Lilla Tar, Birgit Linkus, Luc Dupuis, Philip C. Wong, Albert Ludolph, Francesco Roselli
P88
The fecal microbiome of early-stage ALS patients
David Brenner, Andreas Hiergeist, Carolin Adis, André Gessner, Albert C. Ludolph, Jochen H. Weishaupt

P90
Modeling FUS-ALS hallmark neuropathology using patient-specific iPSCs and iPSC-derived cortical neurons
Julia Japtok, Xenia Lojewski, Marcel Naumann, Moritz Klingenstein, Peter Reinhardt, Jared Sterneckert, Stefan Putz, Maria Demestre, Tobias M. Boeckers, Albert C. Ludolph, Stefan Liebau, Alexander Storch, Andreas Hermann

P92
Dynamics of AGO2 interactions with nuclear ALS proteins in stressed neurons
Revital Ravid, Natali Rivkin, Ronit Pasvolsky, Chen Eitan, Haggai Kaspi, Eran Yanowski, Alon Savidor, Yishai Levin, Eran Hornstein

P94
ALS, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: implications in frontotemporal lobar degeneration
Pol Andrés-Benito, Jesús Moreno, Ester Aso, Mónica Povedano, Isidro Ferrer

P96
Generation of gene knockouts and gene replacements in human cell lines for disease modelling: a cautionary note
Stefan Reber, Jonas Mechtersheimer, Sofia Nasif, Julio Aguila Benitez, Martino Colombo, Michal Domanski, Daniel Jutzi, Eva Hedlund, Marc-David Ruepp

P98
MIF inhibits the formation of misfolded SOD1 amyloid aggregates: implications for familial ALS

P100
Understanding mechanisms of truncating mutations in the FUS gene
Tatyana Shelkovnikova, Haiyan An, Vladimir Buchman

P102
Sensory neuropathy in progressive motor neuronopathy (pmn) mice is associated with defects in microtubule polymerization and axonal transport
Michael K. Schäfer, Sarah Bellouze, Arnaud Jacquier, Sébastien Schaller, Laurence Richard, Stéphane Mathis, Jean-Michel Vallat, Georg Haase
PI04
Interactions between TAU, FUS and TDP-43 in neurodegenerative diseases
Annis-Rayan Bourefis, Luc Dupuis, Valérie Buée, Edor Kabashi

PI06
Profiling of basement membrane proteins in plasma and cerebrospinal fluid within ALS and frontotemporal dementia
Julia Remnestål, Sebastian Lewandowski, Jennie Olofsson, Caroline Graff, Magdalena Kuzma-Kozakiewicz, Albert C. Ludolph, Katrin Marcus, Philip Van Damme, Jan Veldink, John M. Ravits, Anna Månberg, Peter Nilsson

PI08
Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo
Sander Beel, Matthieu Moisse, Louis De Muynck, Wim Robberecht, Ludo Van Den Bosch, Paul Saftig, Philip Van Damme

PI10
Unravelling the molecular mechanisms behind corticospinal motor neuron degeneration in ALS
Christine Marques, Mathieu Fischer, Thibaut Burg, Jelena Scekic-Zahirovic, Anaïs Streit, Céline Keime, Marco A. Mendoza, Caroline Rouaux

PI12
Generation and analysis of ALS-associated hnRnp A knockout zebrafish lines
Lara Jansen, Bettina Schmid

PI14
Mitochondrial Calcium Uniporter expression with disease progression in the G93AhSOD1 mouse model
Vedrana Tadić, Adam Adam, Saikata Sengupta, Thanh-Tu Le, Silke Keiner, Madlen Guenther, Beatrice Stubendorff, Otto W. Witte, Julian Grosskreutz

PI16
Clinical, pathological and molecular characterisation of C9orf72-ALS leads to identification of novel therapeutic targets
Johnathan Cooper-Knock, Adrian Higginbottom, Guillaume Hautbergue, Paul Heath, J. Robin Highley, Christopher J. McDermott, Paul G. Ince, Stephen B. Wharton, Janine Kirby, Pamela J. Shaw
Therapy

PI18
TDP-43-nucleoporin connection: a novel player in ALS?
Omar Ramirez-Núñez, Ana Belen Granado-Serrano, Victoria Ayala, Jordi Boada, Pascual Torres, Mónica Povedano, Isidro Ferrer, Reinald Pamplona, Manuel Portero-Otin

PI20
Oral supplementation with the omega-3 docosahexaenoic acid (DHA) in patients with amyotrophic lateral sclerosis (ALS): a randomized, double-blind, placebo-controlled, pilot study
Elisabet Romero, Monica Povedano, M.Núria Virgili, Maria A. Barceló, Yolanda Martínez, Andrés Paipa, Ainhoa Tejado, Joan-Carles Domingo

PI22
A safety analysis of edaravone (MCI-186) during the first 6-cycles (24 weeks) of ALS therapy from 3 randomized double-blind placebo-controlled trials
Alexander Kalin, Kaoru Ishizaki, Elvia Medina-Paraiso, Alex Kim, Zhang Yannong, Takanori Saita, Masahiko Wasaki

PI24
Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations
Yoshinobu Nakamaru, Atsuhiro Kawaguchi, Shuji Kinoshita, Koji Takei, Joseph M. Palumbo

PI26
A pharmacometabolomics approach in ALS: proof of concept in a clinical trial of olesoxime
Hélène Blasco, Franck Patin, Amandine Descat, Guillaume Garçon, Philippe Corcia, Patrick Gelé, Timothée Lenglet, Vincent Meiningier, David Devos, Jean François Gossens, Pierre-François Pradat
Information for Speakers and Poster Presenters

Poster presentations

Posters will be displayed in the Foyer II throughout the congress. Display boards will be numbered. During the poster session, the presenting authors are kindly asked to be present next to their poster.

Speakers’ Centre

The technical organizer will give you additional instructions concerning your session and the presentation of your paper in the Speakers’ Centre. The Congress staff will ensure that your presentation is downloaded on the computer in your designated session room. Please make sure that your computer presentation is fully operational before your talk. Only Power Point presentations on USB keys and portable hard disks will be accepted. Version MS PowerPoint 2010 is recommended. We suggest that your computer presentation is installed and tested at least two hours before your talk. A technician and a room attendant will provide assistance when needed.

The Speakers’ Centre will have the same opening hours as the registration desk.

Internet

Wireless internet connection is available in Foyer II. The name of the network is CD_GUEST. No login or password is needed.

Registration and Fees

Registration fee:

- Established researchers 245 EUR
- PhD students 175 EUR

Registration (for both established researchers and PhD students) includes:

- Participation at all ENCALS lectures and access to the exhibition area
- Congress bag including programme booklet
- ENCALS Dinner on Friday evening
- Lunch at the exhibition area on Thursday and Friday
- Coffee at the exhibition area during the breaks
**Registration and Information Desk**

The ENCALS Meeting Registration Desk, located in Foyer II of Cankarjev dom, will open as follows:

- **Thursday, 18 May**: 11:00–18:00
- **Friday, 19 May**: 8:00–19:00
- **Saturday, 20 May**: 8:00–13:00

**Social Programme**

**Friday, 19 May 2017**

20:00–22:30

*ENCALS Dinner / Festival Hall (Vilharjeva street II)*

Included in the fee for regular participants.

Additional tickets: 50 EUR / person

Meeting point:

19:30 at Cankarjev dom, Erjavčeva Street (by bus) and return at 22:30

**General Information**

**Conference Identification Badge**

A conference identification badge will be included in the conference material provided upon registration. There will be no admittance to the Scientific Sessions without the conference badge. Invitations to social events will be collected at the entrance.

**Attendance Certificate**

A Certificate of Attendance will be issued to all registered participants.

**Coffee Breaks**

During breaks, refreshments will be served free of charge to participants wearing congress badges.

**Lunches**

Working lunches (standing buffet) are included in the registration fee and will be served at lunchtime in Foyer II.
NOW FOR TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY (TTR-FAP).  
A PROGRESSIVE, FATAL NEURODEGENERATIVE DISEASE.

**Vyndaqel®**  
(tafamidis)  
A breakthrough for TTR-FAP

**Stabilize the protein.**  
**Delay neurologic impairment.**

**Vyndaqel** selectively binds to transthyretin proteins to stabilize them.

**Introducing the Vyndaqel Breakthrough.**

The first and only medication shown to delay the peripheral neurologic impairment associated with TTR-FAP—an irreversible, progressive neurodegenerative disease.

Early diagnosis can make the difference. So can Vyndaqel.

---

**Succinct Information from the Product SmPC**

**Vyndaqel** 20 mg soft capsules

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Health care professionals are asked to report any suspected adverse reactions. See section 4.8 of Summary of Product Characteristics for how to report adverse reactions. Qualitative and quantitative composition: Each soft capsule contains 20 mg tafamidis meglumine equivalent to 12.2 mg tafamidis. Each soft capsule contains no more than 44 mg of sorbitol. Indications: Treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment. Posology and method of administration: Treatment should be initiated by and remain under the supervision of a physician knowledgeable in the management of patients with transthyretin amyloid polyneuropathy. The recommended dose is 20 mg orally once daily. If vomiting occurs after dosing, and the intact capsule is identified, then an additional dose should be administered if possible. If no capsule is identified, then no additional dose is necessary. Elderly data are very limited. Hepatic and renal impairment: Tafamidis meglumine has not been studied in patients with severe hepatic impairment and caution is recommended. Paediatric population: No relevant use. Method of administration: The soft capsules should be swallowed whole, not crushed or cut, and taken with or without food. Contra-indications: Hypersensitivity to the active substance or to any of the excipients. Special warnings and precautions for use: Women of childbearing potential should use appropriate contraception when taking tafamidis meglumine and continue to use appropriate contraception for 1 month after stopping treatment. Vyndaqel should be added to the standard of care for the treatment of the transthyretin familial amyloid polyneuropathy (TTR-FAP) patient. Physicians should monitor patients and continue to assess the need for other therapy, including the need for liver transplantation, as part of this standard of care. As there are no data available regarding the use of tafamidis meglumine post-liver transplantation, it should be discontinued in patients who undergo liver transplantation. Vyndaqel contains sorbitol (820). Patients with rare hereditary problems of fructose intolerance should not take this medicinal product. Interactions: In a clinical study in healthy volunteers, tafamidis meglumine did not induce or inhibit the cytochrome P450 enzyme CYP3A4. In vitro data also indicated that tafamidis meglumine does not significantly inhibit cytochrome P450 enzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. In vitro tafamidis meglumine inhibits transporters BCRP, OATP1B1 and OAT3 and may cause drug-drug interactions at clinically relevant concentrations with substrates of these transporters. No interaction studies have been performed evaluating the effect of other medicinal products or tafamidis meglumine. Fertility, pregnancy and lactation: Contraceptive measures should be used by women of childbearing potential during treatment with tafamidis meglumine, and for one month after stopping treatment, due to the prolonged half-life. There are no data on the use of tafamidis meglumine in pregnant women. Studies in animals have shown reproductive toxicity. Tafamidis meglumine is not recommended during pregnancy and in women of childbearing potential not using contraception. Available data in animals have shown excretion of tafamidis in milk. A risk to the newborn/infants cannot be excluded. Tafamidis meglumine should not be used during breast-feeding. Effects on the ability to drive and use machines: Tafamidis meglumine is believed to have no or negligible influence on the ability to drive or use machines. Undesirable effects: Very common: urinary tract infection, vaginal infection, diarrhoea, upper abdominal pain. Overdosage: The reported treatment-related adverse events were mild to moderate and included: headache, somnolence, myalgia, diarrhoea, nausea, photosensitivity reaction, and pruritus. In case of overdose, standard supportive measures should be instituted as required. Legal status: Medicinal products prescribed and dispensed by medical practice to a specialist physician in the relevant field of medicine or another physician authorized by that specialist. Marketing authorization holder: Pfizer Limited, Ramigata Road, Kent C113, United Kingdom. Date of latest revision of the text: 22/07/2016.

Before prescribing read the complete summary of product characteristics.
Please read prescribing information of the following products: Briviact®, Keppra®, Vimpat®, Neupro®, Nootropil®, Xeomin®, Translarna™, Targinact®, Xyrem®. Product prescribing information can be found on www.ema.europa.eu/ema/
As a leader in muscle biology research, we are dedicated to our mission of improving the lives of people confronting devastating diseases of impaired muscle function.

We are proud to be a Gold Sponsor of the 2017 ENCALS Meeting
We are proud to be a Gold Sponsor of the 2017 ENCALS Meeting

Every day, we are motivated by people living with ALS and other diseases of impaired muscle function. They are spouses, partners, sisters, brothers, children and grandchildren. They are not defined by their disease. They are fighting with spirit, determination and courage. They amaze us. They inspire us. They are our heroes.

cytokinetics.com
motnje: bolnikih z generalizirano anksiozno motnjo je 30 mg enkrat na dan s hrano ali brez nje. Pri bolnikih z neza-

Prekinitev zdravljenja:

Krvavitev: lahko so povezana z večjim tveganjem za krvavitev, ter za bolnikov s hudo jetrno okvaro.

Zato jih jemljejo zdravila proti strjevanju krvi in/ali druga zdravila, ki vplivajo na delovanje

dom: Duloksetin

Sandoz

Gaynor PJ.
Podaljšajte ta trenutek!

SKRAŠAN POMOŽNI LIST ZA UŠTEDNE ZAHLJUJESNI ZDAVILA:  
Izra debla: AZELCT 30 mg in 60 mg je razagilin (v obliki laktoze monohidrata), 0,152 mg barvila sončno rumeno FCF (E110) in 0,390 mg barvila alurno. Gastrorezistentna kapsula vsebuje 60 mg duloksetina (v obliki duloksetinijevega klorida) ter 3,9 mg laktoze.

SESTAVA:
- Duloksetina pri bolnikih z obolenjem jeter, ki ima za posledico okvarjeno delovanje jeter, ne smejo
- Zdravljenje se lahko pojavijo odtegnitveni simptomi. Svetujemo, da se ob prekinjanju zdravljenja odmerek
- Cirozo, dehidriranih bolnikov ali bolnikov, ki jemljejo diuretike.

TERAPEVTSKE INDIKACIJE:
- Za bolnike s samomorom povezanih dogodki v anamnezi, ali bolnikih, ki kažjo znatno stopnjo samomorilne

- Kolikor je to potrebno, da izpostavi bolnike možnemu tveganju verzibilnimi zaviralci monoaminooksidaze (MAOI).

- Pri bolnikih, ki so jemljejo zdravila, ki lahko povzročijo okvaro jeter, je pri bolnikih s hudo jetrno okvaro je kontraindicirana. Uporabi razagilina pri bolnikih z zmerno jetrno okvaro je potrebna previdnost. V primeru,

- Zdravljenje se lahko pojavijo odtegnitveni simptomi. Svetujemo, da se ob prekinjanju zdravljenja odmerek

- Zdravljenje se lahko pojavijo odtegnitveni simptomi. Svetujemo, da se ob prekinjanju zdravljenja odmerek

- Duloksetin je bil pri nekaterih bolnikih povezan s povišanjem krvnega tlaka. Pretek cilja in razpisu.

- Za bolnike s sočasnimi veliki depresivnimi motnjami je začetni in vzdrževalni odmerek 60 mg.

- Za bolnike s sočasnimi veliki depresivnimi motnjami je začetni in vzdrževalni odmerek 60 mg.

- Za bolnike s sočasnimi veliki depresivnimi motnjami je začetni in vzdrževalni odmerek 60 mg.

- Za bolnike s sočasnimi veliki depresivnimi motnjami je začetni in vzdrževalni odmerek 60 mg.

- Za bolnike s sočasnimi veliki depresivnimi motnjami je začetni in vzdrževalni odmerek 60 mg.

- Za bolnike s sočasnimi veliki depresivnimi motnjami je začetni in vzdrževalni odmerek 60 mg.